Drug Trial Radar · NCT07616154
Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Sep 10, 2026
Primary completion
Sep 2034
Study completion Sep 2035
Sponsor
- Lead sponsor
- St. Jude Children's Research HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study it to evaluate a reduced toxicity conditioning regimen for haploidentical donor HCT followed by a GVHD prophylaxis regimen comprising of post-transplant cyclophosphamide, sirolimus and abatacept with the goal to improve the GVHD-free rejection-free survival (GRFS) to greater than 90% after haploidentical donor HCT in children and young adults with SCD. Primary Objective: \- To assess the GVHD-free and rejection free survival (GRFS) after haploidentical donor HCT in children and young adults with SCD. Secondary Objectives: * Assess the overall survival (OS) and disease-free survival (DFS) after haploidentical donor HCT for SCD. * Estimate incidence and severity of acute and chronic GVHD after haploidentical donor HCT for SCD. * Assess the neutrophil and platelet engraftment kinetics after haploidentical donor HCT for SCD.
Conditions
- Sickle Cell Disease
Interventions
Cyclophosphamide 50mgDrug
IV
AbataceptDrug
IV
AlemtuzumabDrug
IV
HydroxyureaDrug
IV
ThiotepaDrug
IV
FilgrastimDrug
IV
SirolimusDrug
IV
AzathioprineDrug
IV
TBIRadiation
Radiaiton therapy
Hematopoietic Progenitor Cell InfusionProcedure
Hematopoietic Progenitor Cell Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- GVHD-free and rejection free survival (GRFS)Time frame: Up to 3 years after HCT
Locations
1 site in 1 country. Site status is shown where the registry gives one.
St Jude Children's Research Hospital
Memphis, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.